Hematopoietic stem cell transplantation for acute lymphoblastic leukemia: why do adolescents and young adults outcomes differ from those of children? A retrospective study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC).

Audrey GrainFanny Rialland-BattistiPatrice ChevallierNicolas BlinJean-Hugues DalleGérard MichelNathalie DhédinRegis Peffault de LatourCécile PochonIbrahim Yakoub-AghaYves BertrandAnne SirventCharlotte JubertEdouard ForcadeAna BerceanuVirginie GandemerPascale SchneiderJacques-Olivier BayPierre-Simon RohrlichEolia BrissotCatherine PaillardDominique PlantazStéphanie Nguyen QuocFanny GonzalesNatacha MaillardLucie PlancheAndré Baruchel

Published in: Journal of cancer research and clinical oncology (2022)

AYA have worse outcomes than children after HSCT for ALL because of a greater risk of TRM due to cGvHD. HSCT practices should be questioned in this population.

Keyphrases

stem cell transplantation
acute lymphoblastic leukemia
high dose
young adults
healthcare
primary care
hematopoietic stem cell
type diabetes
low dose
metabolic syndrome